Evidence map›Paper›PMID 34963005›Full record

ArticleJournal of the National Cancer Institute2022

Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer.

Konstantin Weber-Lassalle, Corinna Ernst, Alexander Reuss, Kathrin Möllenhoff, Klaus Baumann, Christian Jackisch, Jan Hauke, Dimo Dietrich, Julika Borde, Tjoung-Won Park-Simon and 12 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Clonal Hematopoiesis in Women With Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Review
  10. Detection and Characterization of Clonal Hematopoiesis.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  11. Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Article
  12. Review
  13. CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Review
  14. Review
  15. TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia.Mediterranean journal of hematology and infectious diseases · 2023
    Review
  16. Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms.Current hematologic malignancy reports · 2022
    Review
  17. Article
  18. [Clonal hematopoiesis and solid neoplasms].Innere Medizin (Heidelberg, Germany) · 2022
    Review
  19. A Single Nucleotide Polymorphism inCirculation research · 2022
    Article
  20. [Drug-induced bone marrow changes].Pathologie (Heidelberg, Germany) · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 11 institutions in 1 country.

Konstantin Weber-LassalleCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Corinna ErnstCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.ORCID 0000-0001-7756-8815
Alexander ReussCoordinating Center for Clinical Trials, Philipps-University Marburg, Marburg, Germany.
Kathrin MöllenhoffInstitute of Medical Statistics and Computational Biology, Faculty of Medicine, University of Cologne, Cologne, Germany.
Klaus BaumannDepartment of Gynecology, Medical Center Ludwigshafen, Ludwigshafen, Germany.ORCID 0000-0001-5333-9823
Christian JackischDepartment of Gynecology and Obstetrics, Sana Klinikum Offenbach, Offenbach, Germany.ORCID 0000-0001-8537-3743
Jan HaukeCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.ORCID 0000-0001-8236-4075
Dimo DietrichDepartment of Otorhinolaryngology, Head and Neck Surgery, University Medical Center Bonn (UKB), Bonn, Germany.ORCID 0000-0001-9794-7927
Julika BordeCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.ORCID 0000-0003-2448-7872
Tjoung-Won Park-SimonDepartment of Gynecology & Gynecologic Oncology, Medizinische Hochschule Hannover, Hannover, Germany.ORCID 0000-0002-2863-3040
Lars HankerDepartment of Gynecology and Obstetrics, University of Schleswig-Holstein, Lübeck, Germany.ORCID 0000-0001-6697-018X
Katharina PrieskeDepartment of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-4245-6503
Sandra SchmidtCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Nana Weber-LassalleCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Esther Pohl-RescignoCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Stefan KommossDepartment Gynecology & Gynecologic Oncology, University of Tübingen, Tübingen, Germany.ORCID 0000-0003-0534-1501
Frederik MarméCenter for Tumor Disease, Department of Gynecology, University of Heidelberg, Heidelberg, Germany.
Florian HeitzDepartment of Gynecology & Gynecologic Oncology, Kliniken Essen-Mitte (KEM) Evang, Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.ORCID 0000-0002-2412-0352
Julia C StinglInstitute of Clinical Pharmacology, University Hospital of Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany.ORCID 0000-0002-1566-8156
Rita K SchmutzlerCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Philipp HarterDepartment of Gynecology & Gynecologic Oncology, Kliniken Essen-Mitte (KEM) Evang, Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.ORCID 0000-0002-9663-5005
Eric HahnenCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
University of Cologne · DEHeidelberg University · DEHumboldt-Universität zu Berlin · DEKliniken Essen-Mitte · DEKlinikum Ludwigshafen · DEMedizinische Hochschule Hannover · DEPhilipps University of Marburg · DERWTH Aachen University · DESana Klinikum Offenbach · DEUniversität Hamburg · DEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer patients are at risk of secondary therapy-related myeloid neoplasms (t-MNs). Acquired blood-specific mutations in clonal hematopoiesis (CH)-associated genes are t-MN risk factors, and their occurrence associated with cancer therapy and age. Patients with ovarian cancer (OC) showed a particularly high prevalence of CH-associated gene mutations, which may additionally be explained by the high proportion of a hereditary disease cause in this cancer entity.

methodsWe performed a retrospective analysis of 448 OC patients enrolled in the AGO-TR1 study; 249 were enrolled at primary diagnosis and 199 at platinum-sensitive recurrence. Analyses included the most frequently altered CH-associated genes (ASXL1, DNMT3A, GNAS, JAK2, PPM1D, SF3B1, SH2B3, SRSF2, TET2, TP53). Results were analyzed according to the BRCA1/2 germline (gBRCA1/2) mutation status. All statistical tests were 2-sided.

resultsAdvanced age at blood draw and a high number of prior platinum-based chemotherapy lines were risk factors to acquire CH-associated gene mutations, with gene-specific effects observed. Binomial logistic regression suggested increased probabilities for gBRCA1/2 mutation carriers to acquire CH-associated PPM1D and TP53 gene mutations (PPM1D: odds ratio = 4.30, 95% confidence interval = 1.48 to 12.46, P = .007; TP53: odds ratio = 6.20, 95% confidence interval = 0.98 to 53.9, P = .06). This observation was due to a statistically significantly increased number of platinum-based chemotherapy lines in gBRCA1/2 mutation carriers vs noncarriers (PPM1D: mean [SD] = 2.04 [1.27] vs 1.04 [0.99], P < .001; TP53: mean [SD] = 2.83 [1.33] vs 1.07 [1.01], P < .001). No interaction between platinum-based chemotherapy and gBRCA1/2 mutation status with the occurrence of CH-associated gene mutations was observed.

conclusionsA positive gBRCA1/2 mutation status is not a risk factor to acquire CH-associated gene mutations. OC patients may benefit from monitoring CH-associated gene mutations, especially following carboplatin exposure. Future clinical studies are required to assess whether treatment regimen should be adapted according to individual t-MN risks.

Indexed as

Clonal HematopoiesisOvarian NeoplasmsCarcinoma, Ovarian EpithelialHumansMutationRetrospective Studies

Identifiers

PMID34963005
PMCPMC9002281
OpenAlexW4200557730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.